| Vasculitis and related conditions | Lifetime | 27 | FR 4 | 99.56 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 28 | FR 2 | 98.89 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 68 | FR 8 | 98.83 |
| Urticaria and Related Conditions | Lifetime | 111 | FR 7 | 98.78 |
| Eosinophilic Disorders and Syndromes | Lifetime | 137 | FR 11 | 98.73 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 219 | FR 8 | 97.93 |
| Systemic Lupus Erythematosus Research | Lifetime | 624 | FR 32 | 98.18 |
| Vascular Anomalies and Treatments | Lifetime | 100 | FR 18 | 97.43 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 139 | FR 7 | 96.88 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 344 | FR 24 | 96.10 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 128 | FR 4 | 95.65 |
| Renal Diseases and Glomerulopathies | Lifetime | 870 | FR 62 | 96.36 |
| Systemic Sclerosis and Related Diseases | Lifetime | 640 | FR 45 | 95.79 |
| Inflammasome and immune disorders | Lifetime | 976 | FR 48 | 92.75 |
| Kawasaki Disease and Coronary Complications | Lifetime | 421 | FR 16 | 92.36 |
| Dermatological and COVID-19 studies | Lifetime | 497 | FR 27 | 82.36 |
| Whipple's Disease and Interleukins | Lifetime | 643 | FR 52 | 61.05 |
| Vasculitis and related conditions | 2021-2025 | 4 | FR 1 | 99.80 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 2 | FR 1 | 99.55 |
| Urticaria and Related Conditions | 2021-2025 | 20 | FR 1 | 98.76 |
| Vascular Anomalies and Treatments | 2021-2025 | 6 | FR 2 | 98.28 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 25 | FR 3 | 98.90 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 39 | FR 2 | 97.57 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 96 | FR 7 | 94.86 |
| Eosinophilic Esophagitis | 2021-2025 | 339 | FR 9 | 92.75 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 414 | FR 31 | 92.70 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 110 | FR 8 | 87.55 |
| Ocular Diseases and Behçet’s Syndrome | 2021-2025 | 652 | FR 30 | 81.13 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 951 | FR 65 | 80.64 |
| Histiocytic Disorders and Treatments | 2021-2025 | 209 | FR 26 | 70.08 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 342 | FR 9 | 63.75 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 892 | FR 52 | 58.89 |
| Dermatological and Skeletal Disorders | 2021-2025 | 967 | FR 68 | 31.82 |
